Logo image of APPH.DE

APONTIS PHARMA AG (APPH.DE) Stock Fundamental Analysis

FRA:APPH - Deutsche Boerse Ag - DE000A3CMGM5 - Common Stock - Currency: EUR

11.2  -0.25 (-2.18%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to APPH. APPH was compared to 50 industry peers in the Pharmaceuticals industry. APPH has a great financial health rating, but its profitability evaluates not so good. APPH is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

APPH had negative earnings in the past year.
APPH had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: APPH reported negative operating cash flow in multiple years.
APPH.DE Yearly Net Income VS EBIT VS OCF VS FCFAPPH.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 0 5M -5M 10M -10M -15M

1.2 Ratios

APPH's Return On Assets of -14.50% is on the low side compared to the rest of the industry. APPH is outperformed by 72.00% of its industry peers.
APPH's Return On Equity of -21.16% is on the low side compared to the rest of the industry. APPH is outperformed by 70.00% of its industry peers.
Industry RankSector Rank
ROA -14.5%
ROE -21.16%
ROIC N/A
ROA(3y)-5.52%
ROA(5y)-5.67%
ROE(3y)-10.91%
ROE(5y)-23.67%
ROIC(3y)N/A
ROIC(5y)N/A
APPH.DE Yearly ROA, ROE, ROICAPPH.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -10 -20 -30 -40 -50

1.3 Margins

With a Gross Margin value of 60.26%, APPH is not doing good in the industry: 62.00% of the companies in the same industry are doing better.
APPH's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for APPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.58%
GM growth 5YN/A
APPH.DE Yearly Profit, Operating, Gross MarginsAPPH.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 20 -20 40 60

More info and screens

7

2. Health

2.1 Basic Checks

APPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, APPH has about the same amount of shares outstanding.
APPH has a worse debt/assets ratio than last year.
APPH.DE Yearly Shares OutstandingAPPH.DE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2M 4M 6M 8M
APPH.DE Yearly Total Debt VS Total AssetsAPPH.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

There is no outstanding debt for APPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC7.16%
APPH.DE Yearly LT Debt VS Equity VS FCFAPPH.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 10M -10M 20M 30M 40M

2.3 Liquidity

APPH has a Current Ratio of 3.77. This indicates that APPH is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.77, APPH belongs to the top of the industry, outperforming 92.00% of the companies in the same industry.
APPH has a Quick Ratio of 2.74. This indicates that APPH is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.74, APPH belongs to the top of the industry, outperforming 90.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.77
Quick Ratio 2.74
APPH.DE Yearly Current Assets VS Current LiabilitesAPPH.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

APPH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -520.42%.
The Revenue for APPH has decreased by -33.67% in the past year. This is quite bad
The Revenue has been decreasing by -1.97% on average over the past years.
EPS 1Y (TTM)-520.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-33.67%
Revenue growth 3Y-1.97%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

APPH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.94% yearly.
Based on estimates for the next years, APPH will show a very strong growth in Revenue. The Revenue will grow by 22.21% on average per year.
EPS Next Y106.38%
EPS Next 2Y49.98%
EPS Next 3Y35.42%
EPS Next 5Y28.94%
Revenue Next Year37.73%
Revenue Next 2Y26.5%
Revenue Next 3Y23.65%
Revenue Next 5Y22.21%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
APPH.DE Yearly Revenue VS EstimatesAPPH.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M
APPH.DE Yearly EPS VS EstimatesAPPH.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 1 -1

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for APPH. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 25.30, APPH can be considered very expensive at the moment.
The rest of the industry has a similar Price/Forward Earnings ratio as APPH.
The average S&P500 Price/Forward Earnings ratio is at 21.38. APPH is around the same levels.
Industry RankSector Rank
PE N/A
Fwd PE 25.3
APPH.DE Price Earnings VS Forward Price EarningsAPPH.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APPH.DE Per share dataAPPH.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as APPH's earnings are expected to grow with 35.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.98%
EPS Next 3Y35.42%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for APPH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APONTIS PHARMA AG

FRA:APPH (4/25/2025, 7:00:00 PM)

11.2

-0.25 (-2.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-26 2025-03-26/amc
Earnings (Next)N/A N/A
Inst Owners45.55%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap95.20M
Analysts43.33
Price Target13.77 (22.95%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.18%
PT rev (3m)8.18%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-2.63%
EPS NY rev (3m)-13.28%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 25.3
P/S 1.49
P/FCF N/A
P/OCF N/A
P/B 3.06
P/tB 3.06
EV/EBITDA N/A
EPS(TTM)-0.76
EYN/A
EPS(NY)0.44
Fwd EY3.95%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS7.51
BVpS3.66
TBVpS3.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.5%
ROE -21.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.26%
FCFM N/A
ROA(3y)-5.52%
ROA(5y)-5.67%
ROE(3y)-10.91%
ROE(5y)-23.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.58%
GM growth 5YN/A
F-ScoreN/A
Asset Turnover1.41
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.77
Quick Ratio 2.74
Altman-Z N/A
F-ScoreN/A
WACC7.16%
ROIC/WACCN/A
Cap/Depr(3y)150.19%
Cap/Depr(5y)135.8%
Cap/Sales(3y)5.98%
Cap/Sales(5y)4.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-520.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y106.38%
EPS Next 2Y49.98%
EPS Next 3Y35.42%
EPS Next 5Y28.94%
Revenue 1Y (TTM)-33.67%
Revenue growth 3Y-1.97%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year37.73%
Revenue Next 2Y26.5%
Revenue Next 3Y23.65%
Revenue Next 5Y22.21%
EBIT growth 1Y-392.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year121.52%
EBIT Next 3Y41.8%
EBIT Next 5Y32.36%
FCF growth 1Y-304.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-214.3%
OCF growth 3YN/A
OCF growth 5YN/A